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ABSTRACT
There is no curative treatment for patients with diffuse intrinsic pontine glioma
(DIPG). However, with the recent availability of biopsy and autopsy tissue, new
data regarding the biologic behavior of this tumor have emerged, allowing greater
molecular characterization and leading to investigations which may result in improved
therapeutic options. Treatment strategies must address both primary disease sites
as well as any metastatic deposits, which may be variably sensitive to a particular
approach.
In this case report, we present a patient with DIPG treated with irradiation and
serial investigational agents. The clinical, pathological and molecular phenotypes
of both the progressive primary tumor as well as concomitant metastatic deposits
obtained at autopsy are discussed. While some mRNA differences were demonstrated,
all analyzed sites of disease shared similar mutational arrangements, suggesting that
targeting the mutations of the primary tumor may be effective for all sites of disease.

INTRODUCTION

and lead to improvement in treatments. We describe a
case of progressive disease at both the primary and two
new metastatic points, and present the molecular and
pathological features of the primary and metastatic tumor.

Diffuse intrinsic pontine glioma (DIPG) is a subset
of pediatric brainstem glioma with an abysmal median
survival of 10-12 months despite multiple clinical trials
testing myriad new treatments.[1] The majority of
DIPG tumors progress locally but metastases can occur.
[2, 3] Due to the rarity of available tissue, most studies
have not analyzed the molecular and pathological
differences between primary and metastatic disease. These
differences may inform our conceptualization of DIPG
www.impactjournals.com/oncotarget

CASE PRESENTATION
A previously healthy 9-year-old female presented
to her primary care physician after developing left-sided
facial weakness. She was referred for magnetic resonance
imaging (MRI) which showed T2/FLAIR hyperintensity
1
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Tissue analysis

centered within and expanding the pons. The initial
physical exam revealed several neurological abnormalities
including a left 6th nerve palsy with bilateral nystagmus
as well as an incomplete left facial palsy and left-sided
dysmetria.

Coronal sections of the post-mortem brain showed
the SP tumor: a large, ill-defined metastatic solid mass
centered at the septum pellucidum and involving the
corpus callosum, right internal capsule, and the frontal
horns of the lateral ventricles. Autopsy also revealed the
PH lesion: a smaller lesion centered in the left posterior
hippocampus. The basis pontis was significantly expanded,
while the cerebellum was grossly normal.
Histological analysis was undertaken of multiple
sites in both the primary and the two metastatic tumor
sites, showing that the SP tumor, much like the primary
site, was overall best classified as high-grade (WHO
Grade IV, Figure 2) while the PH tumor was lower grade;
nevertheless, all sites of disease displayed focal necrosis
and vascular proliferation. The metastatic tumors had
scattered areas of small, round blue cells reminiscent of
PNET, but were strongly diffusely positive for GFAP,
negative for synaptophysin and were overall best
classified as glioma. Metastatic disease in the SP tumor
had an increased Ki67 proliferation index compared
to the brainstem lesion, 30% vs. 8%, respectively.
All tumor sites displayed positive staining for the
histone 3 K27M (H3K27M) mutation with less evident
histological staining for wild type histone 3 trimethylation
(H3K27me3) (Figure 2). The tumors were also positive for
CD45 representing various degrees of infiltrating resident
microglia and macrophages (Figure 2).
We extracted mRNA from six brain locations to
attempt to differentiate metastatic from primary tumor

Treatments administered
The patient was enrolled on a Children’s Oncology
Group trial with vorinostat and focal radiation therapy; the
post-radiation MRI revealed improvement in the pontine
lesion with decreased mass effect. However, seven months
later the pontine glioma increased in size and two new
metastases were simultaneously noted: 1) a large lesion
of the septum pellucidum involving the frontal horns of
the lateral ventricles and the undersurface of the anterior
corpus callosum (labeled ‘SP’ metastatic point), and 2)
a left posterior hippocampal lesion (labeled ‘PH’ lesion)
(Figure 1A, 1B).
The patient was next enrolled in a Pediatric Brain
Tumor Consortium trial and received two doses of a
telomerase inhibitor which was discontinued for reasons
unrelated to the patient’s clinical course, and she was
noted to have subsequent progression of both the primary
and metastatic lesions. After the patient died, an autopsy
was performed within 10 hours of death, and fresh-frozen
and formalin fixed tissue was obtained from the primary
site and the disseminated lesions as well as the grossly
normal brain.

Figure 1: A. Sagittal SPGR of brainstem tumor progression and B. Axial T2 FLAIR contrasted images of concomitant metastatic lesion
growth.
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Table 1: Genes exhibit significant differential expression (ANOVA analysis)
between the primary brainstem tumor and separate portions of the SP
metastatic tumor, as well as between the major portions of the SP tumor
(ventricular portion versus frontal lobe portion).
Brainstem vs. Ventricular Portion (SP)
Gene

Fold Change

p-value

CCND2
FGFR3
MLH1

2.71
2.36
-1.53

8.89E-03
1.99E-02
1.79E-02

ERBB4

-1.68

1.73E-02

AR
TP53
PTPRG
PML
NPM1

-1.82
-2.07
-2.30
-2.59
-2.71

1.31E-02
2.54E-02
7.04E-03
6.30E-03
1.95E-02

BRCA1

-2.80

1.07E-02

PTK7
KIT
MYCN
LMO1
E2F3
BRCA2
GATA1
RAD54L
CDC25C

-2.81
-2.98
-3.20
-4.12
-4.77
-4.87
-5.29
-5.55
-6.30

9.22E-03
2.38E-03
1.53E-02
1.23E-02
4.42E-06
7.62E-05
2.38E-02
6.68E-03
4.02E-05

MYB

-6.97

1.02E-02

WT1
WEE1

-10.96
-12.09

1.23E-02
8.82E-03

Brainstem vs. Right Frontal Lobe (SP)
Gene

Fold Change

p-value

FGFR3

3.37

2.19E-02

CCND2

2.64

1.79E-02

IFNGR1
BRCA2

1.46
-1.55

1.05E-03
4.04E-02

E2F3
PML
CDC25C
GATA1

-1.92
-1.99
-3.05
-7.64

6.08E-04
4.24E-02
1.38E-03
1.38E-02

Ventricular Portion (SP) vs. Right Frontal Lobe (SP)
Gene

Fold Change

p-value

LMO1
TP53
WEE1
WT1
BRCA2

8.60
4.52
3.63
3.30
3.14

1.81E-02
1.86E-02
3.69E-02
5.32E-02
2.91E-04

MYB

2.78

4.82E-02

E2F3
RAD54
BRCA1
MLH1
CDC25C

2.49
2.35
2.17
2.09
2.07

2.46E-05
3.91E-02
3.77E-02
1.32E-02
4.17E-04

KIT

1.75

1.90E-02

AR

1.61

4.54E-02

PTPRG

1.55

5.38E-02

IFNGR1

1.44

1.45E-03
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based on molecular signature, including three locations
from the brainstem tumor and 3 sites from the SP tumor
(right and left ventricular portions as well as the right
frontal portion). No mRNA could be extracted from the
PH lesion due to fixation issues. mRNA profiling was
completed using the NanoString platform (Cancer Panel)
and the differential mRNA expression pattern between the
primary brainstem and metastatic tumors was assessed
using Partek Genomic Suite software. mRNA profiles of
different sites of the large SP tumor were variably similar
to the brainstem tumor (Figure 3). Ingenuity pathway
analysis revealed that p53 signaling, cell cycle regulation,
DNA damage response, growth arrest and DNA damageinducible 45 (GADD45), and ATM signaling were
common tumorigenic pathways between primary and all
sites of the SP tumor. We identified differentially expressed
mRNA species between the primary tumor compared to
the ventricular portion (twenty-two species) or the frontal
portion (eight species) of the metastatic SP tumor (fold
change > 1.5; < -1.5; p < 0.05) (Table 1). For example,
expression of the fibroblast growth factor receptor,
FGFR3, is up regulated in the brainstem compared to
metastatic tumor samples. However, the overall mRNA
profiles of these differentially expressed genes primarily
exhibit dysfunction of cell cycle regulatory pathways

(Table 1). Given the complexities of histological staining
for tumor assessment, these identified mRNA profiles may
have clinical relevance in rapid identification of potential
therapeutic targets.

DISCUSSION
DIPG continues to have a poor prognosis. Focal
radiation therapy remains the primary treatment modality
and despite multiple clinical trials, chemotherapy has
yet to significantly improve overall survival due to
both local progression and metastatic recurrence.[1, 4]
Because our patient had unusual synchronous growth of
both primary and metastatic lesions, this case offered the
rare opportunity to compare the histopathological and
molecular characteristics of both primary and metastatic
tumors at similar biological time points, which may offer
insight in constructing optimal treatment strategies.
Recently, advances have been made in
understanding the molecular phenotype of DIPG. While
DIPG histology can be heterogeneous, ranging from
lower-grade astrocytoma to higher-grade astrocytoma,[5]
H3.3 K27M mutations have been well described in over
two-thirds of DIPGs[2] and may portend a worse overall
survival.[5, 6] PDGFRA, MYC and PVT1 amplifications,

Figure 2: Immunostaining of primary site of tumor and tumor metastases to left hippocampus (WHO grade II,
PH lesion), and SP tumor: right thalamus (WHO grade II), left ventricle (WHO grade II), right ventricle (WHO
grade IV) and right frontal lobe (WHO grade IV) show histone 3 K27M (H3K27M) mutation and decreased H3K27
trimethylation (H3K27me3). Tumorigenesis is indicated by hypercellularity and proliferative nature indicated by H&E (a) and Ki67
(b) stains, respectively. The positive immunostaining in tumor regions (c, d) represents H3K27M mutant antigen (c) and H3K27me3 status
(d). The positive stain of CD45 shows the microglial infiltration (e). ATRX staining is negative in all the tumor types (f).
www.impactjournals.com/oncotarget
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ATRX, ACVR1 and TP53 mutations and alternative
lengthening of telomeres have also been associated with
DIPG.[5, 7, 8] Also, a higher incidence of metastases in
DIPG than previously appreciated has been described in
recent publications, although our case is the first report
of comprehensive phenotypic analysis comparing multiple
sites in both primary and distant tumor.[2, 5]
In this case, despite histopathological variability

among the primary and metastatic sites, all were positive
for the H3K27M mutation, highlighting the possible
discrepancy between histologic appearance and mutational
status. The retention of the same mutational status in
multiple metastatic sites is particularly important, as
therapy designed to target a particular genetic phenotype
must be able to rely on conservation of the same mutation
in all sites of disease. Conversely, mRNA analyses clearly

Figure 3: Principal component analysis of differentially expressed mRNA species in brainstem, metastatic right frontal
lobe, and metastatic lateral ventricular tumor samples.
www.impactjournals.com/oncotarget
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identified a small cohort of genes differentiating the
primary tumor from different portions of the metastatic
SP tumor. These data are at an mRNA level and are based
on limited probe sets (NanoString); thus, further validation
using genomics and proteomics is warranted. Overall,
mRNA expression and pathway analysis indicate deregulation of cell cycle regulatory pathways. Differences
in site-specific mRNA expression may impact effective
combinations of therapy that target specific biological
pathways, although therapy designed to target epigenetic
and cell cycle regulatory mechanisms may be applicable
to all sites of disease. Further, the significant differences
in mRNA expression even from different locations of the
same tumor implies that single biopsy analysis for mRNA
expression may be misleading in designing comprehensive
targeted treatment plans.
The advent of groundbreaking scientific discoveries
in DIPG will continue to rely on the study of tumor tissue
at diagnosis and after intervention. This case displays
the potential for therapies to address both primary and
metastatic tumors, but further validation of the mutational
synchrony between disease sites is necessary before
reaching broadly applicable conclusions.
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